Thermo Fisher Scientific Inc. $TMO Shares Sold by Ascent Group LLC

Ascent Group LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.4% in the second quarter, HoldingsChannel reports. The fund owned 7,844 shares of the medical research company’s stock after selling 1,007 shares during the quarter. Ascent Group LLC’s holdings in Thermo Fisher Scientific were worth $3,180,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of TMO. Brighton Jones LLC raised its position in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Vest Financial LLC raised its position in shares of Thermo Fisher Scientific by 73.4% during the 1st quarter. Vest Financial LLC now owns 3,188 shares of the medical research company’s stock worth $1,586,000 after purchasing an additional 1,349 shares during the last quarter. Signal Advisors Wealth LLC raised its position in shares of Thermo Fisher Scientific by 7.2% during the 1st quarter. Signal Advisors Wealth LLC now owns 1,297 shares of the medical research company’s stock worth $646,000 after purchasing an additional 87 shares during the last quarter. Finally, Eagle Rock Investment Company LLC raised its position in shares of Thermo Fisher Scientific by 0.3% during the 1st quarter. Eagle Rock Investment Company LLC now owns 7,489 shares of the medical research company’s stock worth $3,727,000 after purchasing an additional 26 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $543.88 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The firm’s fifty day simple moving average is $482.58 and its 200-day simple moving average is $447.27. The firm has a market capitalization of $205.37 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business earned $5.37 EPS. The company’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Analysts Set New Price Targets

TMO has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. HSBC reaffirmed a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.